2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Kirsh says while experts thought prostate cancer care was rapidly advancing 5 or 6 years ago, the next few years will be even more exciting, with new oral androgen receptor agents, PARP inhibitors coming forward, and perhaps new immunotherapies.
While there have been several new agents made available in the past 4 or 5 years, Kirsh says he believes the number of products will more than double in the next 5 years.